The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
9 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $32,999,144 in first-year total cost, median $3,937,322.
Most frequent study sections
- Medication Development Research Study Section[NIDA-L]8
- Special Emphasis Panel[ZDA1 SUY-M (J1)]1
Most frequent institutions
- ANEBULO PHARMACEUTICALS, INC.1
- BIOCORRX PHARMACEUTICALS INC1
- CESSATION THERAPEUTICS, LLC1
- ENSYSCE BIOSCIENCES, INC.1
- JOHNS HOPKINS UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Multi Site Randomized Trial of a GLP-1/GIP Receptor Agonist for Smoking Cessation1U01DA064384-01 | HENDERSHOT, CHRISTIAN SKING, ANDREA CMCKEE, SHERRY ANNSCHACHT, JOSEPH P. | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $2,828,440 | NIDA |
| 2025 | Development of the anti-fentanyl monoclonal antibody, CSX-1004, for prophylaxis against fentanyl and fentanyl analog overdose1U01DA063352-01 | BARRETT, ANDREW | CESSATION THERAPEUTICS, LLC, CA | $2,612,736 | ZDA1 |
| 2024 | Phase III double-blind, randomized controlled trial of suvorexant versus placebo to treat insomnia in persons with opioid use disorder1U01DA060708-01 | HUHN, ANDREW S | JOHNS HOPKINS UNIVERSITY, MD | $6,175,490 | NIDA |
| 2024 | Select Late-Stage CMC, Non-clinical Studies, and Quality Programs to Accelerate NRS-033 Towards Pivotal Studies and Registration in Opioid Use Disorder1U01DA061643-01 | SHAH, NIKEJSORENSON, MARK | NIRSUM LABORATORIES, INC., NY | $4,785,001 | NIDA |
| 2024 | PF614-MPAR: clinical development of opioid with oral overdose protection1U01DA059791-01A1 | KIRKPATRICK, LYNN | ENSYSCE BIOSCIENCES, INC., CA | $4,572,695 | NIDA |
| 2024 | Efficacy, safety, and pharmacokinetic study of BICX104 naltrexone subcutaneous implant alone and in combination with bupropion for the treatment of Methamphetamine Use Disorder (MUD).1U01DA059994-01 | BEEBE DEVARNEY, KATHERINE | BIOCORRX PHARMACEUTICALS INC, CA | $4,131,123 | NIDA |
| 2024 | Development of the novel mu-opioid receptor antagonist methocinnamox (MCAM) for preventing relapse and overdose1U01DA060704-01A1 | FRANCE, CHARLES P | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER, TX | $3,937,322 | NIDA |
| 2024 | Development of an intravenous CB1 antagonist for acute cannabinoid intoxication and cannabis hyperemesis syndrome1U01DA059995-01 | CUNDY, KENNETH | ANEBULO PHARMACEUTICALS, INC., TX | $892,290 | NIDA |
| 2023 | Safety/Toxicology, ADME and CMC Activities to Support the Assessment of the mGlu2 PAM SBP-9330 in a Phase 2 Clinical Study in Smokers1U01DA057847-01A1 | ANTHENELLI, ROBERT MCOSFORD, NICHOLAS DAVIDVELICELEBI, GONUL | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $3,064,047 | NIDA |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.